IN2012DN03042A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03042A
IN2012DN03042A IN3042DEN2012A IN2012DN03042A IN 2012DN03042 A IN2012DN03042 A IN 2012DN03042A IN 3042DEN2012 A IN3042DEN2012 A IN 3042DEN2012A IN 2012DN03042 A IN2012DN03042 A IN 2012DN03042A
Authority
IN
India
Prior art keywords
neuropeptide
obesity
diabetes
substituents
fragments
Prior art date
Application number
Inventor
Karin Conde-Knape
Waleed Danho
Nader Fotouhi
David C Fry
Wajiha Khan
Anish Konkar
Cristina Martha Rondinone
Joseph Swistok
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN03042A publication Critical patent/IN2012DN03042A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
IN3042DEN2012 2009-10-13 2010-10-08 IN2012DN03042A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25089609P 2009-10-13 2009-10-13
PCT/EP2010/065060 WO2011045232A2 (en) 2009-10-13 2010-10-08 Neuropeptide-2 receptor (y-2r) agonists

Publications (1)

Publication Number Publication Date
IN2012DN03042A true IN2012DN03042A (en) 2015-07-31

Family

ID=43478048

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3042DEN2012 IN2012DN03042A (en) 2009-10-13 2010-10-08

Country Status (7)

Country Link
US (1) US20110172147A1 (en)
EP (1) EP2488195A2 (en)
JP (1) JP2013507414A (en)
CN (1) CN102596228A (en)
CA (1) CA2776302A1 (en)
IN (1) IN2012DN03042A (en)
WO (1) WO2011045232A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
HRP20181447T1 (en) 2012-03-22 2018-11-02 Novo Nordisk A/S GLP-1 PEPTIDE PREPARATIONS AND THEIR PREPARATION
EP2708243A1 (en) * 2012-09-17 2014-03-19 OntoChem GmbH Receptor ligand linked cytotoxic molecules
KR102272671B1 (en) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Oral dosing of glp-1 compounds
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
CN105722526B (en) 2013-11-15 2020-12-08 诺和诺德股份有限公司 Selective PYY compounds and their uses
MA41898A (en) * 2015-04-10 2018-02-13 Hoffmann La Roche BICYCLIC QUINAZOLINONE DERIVATIVES
TWI694082B (en) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 Selective PY compound and its use
JP6898518B2 (en) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス A solid composition comprising a GLP-1 agonist, a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid and a lubricant.
CN109678930B (en) * 2018-12-05 2022-04-29 西北工业大学 Polyethylene glycol modified NPFF and its use
CN120092752B (en) * 2025-05-09 2026-04-07 北京大学人民医院 Animal Models of Trigeminal Neuralgia, Their Construction Methods and Applications

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB779829A (en) 1953-11-20 1957-07-24 Ciba Ltd Polyglycol ethers and their manufacture
BE667886A (en) 1965-04-23
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5962263A (en) * 1998-01-08 1999-10-05 Incyte Pharmaceuticals, Inc. Human membrane recycling proteins
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
RU2527893C2 (en) 2004-07-19 2014-09-10 Биокон Лимитед Insulin-oligomer conjugates, preparations and applications thereof
WO2006049681A2 (en) * 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (en) * 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists
CA2630649A1 (en) * 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
NZ584558A (en) * 2007-09-11 2012-10-26 Kode Biotech Ltd Peptide-lipid constructs and their use in diagnostic and therapeutic applications
CN102202681A (en) * 2008-11-05 2011-09-28 霍夫曼-拉罗奇有限公司 Neuropeptide-2 receptor (Y-2R) agonists and uses thereof

Also Published As

Publication number Publication date
JP2013507414A (en) 2013-03-04
WO2011045232A3 (en) 2011-06-16
CA2776302A1 (en) 2011-04-21
US20110172147A1 (en) 2011-07-14
WO2011045232A2 (en) 2011-04-21
EP2488195A2 (en) 2012-08-22
CN102596228A (en) 2012-07-18

Similar Documents

Publication Publication Date Title
IN2012DN03042A (en)
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
TW200806311A (en) Neuropeptide-2 receptor-agonists
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
MX2009007180A (en) Piperidine gpcr agonists.
MX2009012285A (en) Diacylglycerol acyltransferase inhibitors.
MY149622A (en) Pyrazoles as 11-beta-hsd-1
MX2009011802A (en) Imidazoquinolines with immuno-modulating properties.
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
GB0812642D0 (en) Compounds
MX2011012122A (en) Thiophene derivatives.
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
IN2012DN01233A (en)
IN2012DN03182A (en)
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
IN2012DN02139A (en)
MX2012000704A (en) Gpr119 agonists.
MX2009000169A (en) Purinone derivatives as hm74a agonists.
PH12013502204A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
MX2010006108A (en) Inhibitors of stearoyl-coa desaturase.
MY160728A (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
MX2013008431A (en) Mineralocorticoid receptor antagonists.
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
MX2009013501A (en) Piperidine compounds and uses thereof.
UA99787C2 (en) Lactams as beta secretase inhibitors